Protective effects of BP-1-102 against intracranial aneurysms-induced impairments in mice
The development of non-invasive pharmacological therapies to prevent the progression and rupture of intracranial aneurysms (IAs) is an important field of research. This study attempts to reveal the role of BP-1-102, an oral bioavailable signal transducer and activator of transcription 3 (STAT3) inhibitor, in IA. We first constructed an IA mouse model by injecting elastase into the cerebrospinal fluid with simultaneous induction of hypertension by deoxycorticosterone acetate (DOCA) implantation. The results showed that the proportion of IA rupture in mice after BP-1-102 administration was significantly reduced, and the survival time was significantly extended. Further research showed that compared with the vehicle group, the proportion of macrophages infiltrated at the aneurysm and the expression of pro-inflammatory cytokines in the BP-1-102 administration group were significantly reduced. The contractile phenotype vascular smooth muscle cell (VSMC) specific markers, SM22α and αSMA, were significantly upregulated in the BP-1-102 group. Furthermore, we found that BP-1-102 inhibited the expression of critical proteins in the nuclear factor kappa-B and Janus kinase 2/STAT3 signalling pathways. Our study shows that BP-1-102 significantly decreases the rupture of IA, reduces the inflammatory responses and modulates the phenotype of VSMCs, suggesting that BP-1-102 could be utilised as a potential intervention drug for IA.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
---|---|
Enthalten in: |
Journal of drug targeting - 29(2021), 9 vom: 23. Nov., Seite 974-982 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jiang, Zhixian [VerfasserIn] |
---|
Links: |
---|
Anmerkungen: |
Date Completed 15.02.2022 Date Revised 15.02.2022 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1080/1061186X.2021.1895817 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM322397863 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM322397863 | ||
003 | DE-627 | ||
005 | 20231225181945.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1080/1061186X.2021.1895817 |2 doi | |
028 | 5 | 2 | |a pubmed24n1074.xml |
035 | |a (DE-627)NLM322397863 | ||
035 | |a (NLM)33682559 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jiang, Zhixian |e verfasserin |4 aut | |
245 | 1 | 0 | |a Protective effects of BP-1-102 against intracranial aneurysms-induced impairments in mice |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 15.02.2022 | ||
500 | |a Date Revised 15.02.2022 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a The development of non-invasive pharmacological therapies to prevent the progression and rupture of intracranial aneurysms (IAs) is an important field of research. This study attempts to reveal the role of BP-1-102, an oral bioavailable signal transducer and activator of transcription 3 (STAT3) inhibitor, in IA. We first constructed an IA mouse model by injecting elastase into the cerebrospinal fluid with simultaneous induction of hypertension by deoxycorticosterone acetate (DOCA) implantation. The results showed that the proportion of IA rupture in mice after BP-1-102 administration was significantly reduced, and the survival time was significantly extended. Further research showed that compared with the vehicle group, the proportion of macrophages infiltrated at the aneurysm and the expression of pro-inflammatory cytokines in the BP-1-102 administration group were significantly reduced. The contractile phenotype vascular smooth muscle cell (VSMC) specific markers, SM22α and αSMA, were significantly upregulated in the BP-1-102 group. Furthermore, we found that BP-1-102 inhibited the expression of critical proteins in the nuclear factor kappa-B and Janus kinase 2/STAT3 signalling pathways. Our study shows that BP-1-102 significantly decreases the rupture of IA, reduces the inflammatory responses and modulates the phenotype of VSMCs, suggesting that BP-1-102 could be utilised as a potential intervention drug for IA | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, Non-U.S. Gov't | |
650 | 4 | |a BP-1-102 | |
650 | 4 | |a Intracranial aneurysm (IA) | |
650 | 4 | |a inflammatory responses | |
650 | 4 | |a macrophages infiltration | |
650 | 4 | |a signal transducer and activator of transcription 3 (STAT3) | |
650 | 4 | |a vascular smooth muscle cells (VSMCs) | |
650 | 7 | |a Aminosalicylic Acids |2 NLM | |
650 | 7 | |a BP-1-102 |2 NLM | |
650 | 7 | |a Cytokines |2 NLM | |
650 | 7 | |a STAT3 Transcription Factor |2 NLM | |
650 | 7 | |a Stat3 protein, mouse |2 NLM | |
650 | 7 | |a Sulfonamides |2 NLM | |
700 | 1 | |a Huang, Jiaxin |e verfasserin |4 aut | |
700 | 1 | |a You, Lingtong |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Jinning |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of drug targeting |d 1996 |g 29(2021), 9 vom: 23. Nov., Seite 974-982 |w (DE-627)NLM074733958 |x 1029-2330 |7 nnns |
773 | 1 | 8 | |g volume:29 |g year:2021 |g number:9 |g day:23 |g month:11 |g pages:974-982 |
856 | 4 | 0 | |u http://dx.doi.org/10.1080/1061186X.2021.1895817 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 29 |j 2021 |e 9 |b 23 |c 11 |h 974-982 |